Table 4 Results of regression analysis of processeda quarterly health costs in first two years after baseline (N = 2059)
Reference | Estimate | CI 95% | p-value | ||
|---|---|---|---|---|---|
2.5% | 97.5% | ||||
Study group | Control group | −298.58 | − 1312.13 | 714.97 | 0.5635 |
Residential area (Berlin vs rural) | Rural | 262.69 | − 101.60 | 626.98 | 0.1575 |
Interaction: Group x Residential area | 407.35 | 407.35 | 1493.06 | 0.4619 | |
Age group | |||||
46–50 years | 41–45 years | 2832.23 | − 782.80 | 6447.27 | 0.1246 |
51–55 years | 41–45 years | 2875.11 | −606.67 | 6356.89 | 0.1055 |
56–60 years | 41–45 years | 2600.31 | −823.07 | 6023.69 | 0.1365 |
61–65 years | 41–45 years | 2569.53 | −820.65 | 5959.71 | 0.1373 |
66–70 years | 41–45 years | 2840.77 | − 533.57 | 6215.11 | 0.0989 |
71–75 years | 41–45 years | 3259.24 | − 109.66 | 6628.14 | 0.0579 |
76–80 years | 41–45 years | 3318.69 | − 50.93 | 6688.32 | 0.0536 |
81–85 years | 41–45 years | 3017.17 | −356.79 | 6391.14 | 0.0796 |
86–90 years | 41–45 years | 2919.52 | − 469.23 | 6308.27 | 0.0913 |
91–95 years | 41–45 years | 2870.68 | − 689.65 | 6431.00 | 0.1140 |
Sex | Male | −96.52 | − 369.46 | 176.42 | 0.4881 |
NYHA class | |||||
NYHA II | NYHA I | 314.97 | −757.31 | 1387.24 | 0.5646 |
NYHA III | NYHA I | 375.11 | − 696.74 | 1446.96 | 0.4926 |
NYHA IV | NYHA I | 776.31 | −302.57 | 1855.18 | 0.1584 |
Hospitalizations related to CHF | (continuous) | −27.61 | − 195.63 | 140.40 | 0.7472 |
Baseline health costs | (continuous) | 0.34 | 0.29 | 0.39 | < 0.0001*** |
Intake of medication related to CHF (yes / no by groups of agents) | |||||
Angiotensin-converting enzyme | no | −251.08 | − 520.92 | 18.76 | 0.0682 |
Beta-blocker | no | − 470.81 | − 741.91 | −199.71 | 0.0007*** |
Renin-inhibitors | no | −283.79 | − 1553.61 | 986.03 | 0.6612 |
Cardiac glycosides | no | 97.57 | − 252.61 | 447.75 | 0.5848 |
Diuretics | no | 533.86 | 247.94 | 819.78 | 0.0003*** |
AT1 receptor blocker | no | −140.25 | −491.33 | 210.83 | 0.4335 |
Mental and behavioral disorders (yes / no by blocks of ICD-10 Chapter V) | |||||
F00 – F09 (Organic, including symptomatic, mental disorders) | no | 386.31 | −87.09 | 859.70 | 0.1097 |
F10 – F19 (Mental and behavioral disorders due to psychoactive substance use) | no | −83.55 | − 544.49 | 377.39 | 0.7223 |
F20 – F29 (Schizophrenia, schizotypal and delusional disorders) | no | − 288.83 | − 1375.19 | 797.53 | 0.6021 |
F30 – F39 (Mood [affective] disorders) | no | 30.78 | − 326.67 | 388.23 | 0.8659 |
F40 – F49 (Neurotic, stress-related and somatoform disorders) | no | 11.66 | − 351.60 | 374.92 | 0.9498 |
F50 – F59 (Behavioral syndromes associated with physiological disturbances and physical factors) | no | −86.95 | − 775.45 | 601.54 | 0.8044 |
F60 – F69 (Disorders of adult personality and behavior) | no | 816.43 | − 367.37 | 2000.23 | 0.1764 |
F70 – F79 (Mental retardation) | no | 291.70 | − 2155.13 | 2738.54 | 0.8152 |
F80 – F89 (Disorders of psychological development) | no | – | – | – | – |
F90 – F98 (Behavioral and emotional disorders with onset usually occurring in childhood and adolescence) | no | −340.42 | − 2933.64 | 2252.80 | 0.7969 |
F99 – F99 (Unspecified mental disorders) | no | 5878.45 | − 562.31 | 12,319.21 | 0.0736 |
Intercept | – | − 1689.37 | − 5226.05 | 1847.32 | 0.3490 |